Basic Immunology Final; practice questions
NAME____________________________________
MCB 4211,
Student ID#__________________________________
Page 4 of 8
e.
Recombinant T cell receptors that have been engineered to include an antigen binding region that
is specific for a tumor-specific- or tumor-associated-transplantation antigen and coupled to a
transmembrane region and a signaling region are transfected into host T cells before reinsertion
in the patient. This establishes a durable immunity against the tumor
17.
Which of the following is
NOT
a function of metallothionein?
a.
Decrease toxic effect of heavy metals
b.
Acts as a free radical scavenger
c.
Metabolizes cysteine residues
d.
Serves as a reservoir for essential heavy metals
e.
Interacts with membrane bound receptors
18.
If metallothionein is injected in a mouse that is injected with collagen to induce a rheumatoid arthritis-
like condition, it has been found to:
a.
Decrease the severity of joint damage
b.
Alter anti- and pro-inflammatory cytokine levels
c.
have no obvious effect in treated mice
d.
A and B
e.
none of the above are true
19.
Why are camelid antibodies (for example llama antibodies) a useful potential therapeutic treatment?
a.
they are very heat-stable antibodies
b.
these antibodies can function in the presence of detergents and other molecules that would
disrupt antibodies from other mammals
c.
these antibodies are much smaller and thus are better able to reach further into tissues
d.
answers a,b, and c are all true
e.
all of the above answers are false
20.
Which of the following is
NOT
true about HIV binding (attachment) to a target cell?
a.
GP120 binds to a receptor on CD4+ cells
b.
HIV binding requires a receptor
c.
Binding triggers fusion of the viral and host cell membranes
d.
Nucleoside analogs interfere with GP120 rearrangement required for binding
e.
CCR5 and CXCR4 mutations can block HIV from entering the cell
21.
Hepatitis B vaccines are composed of the hepatitis B virus surface antigen and do not intact virus. This
is an example of a(n) _____________ vaccine.
a.
Live virus vaccine
b.
Attenuated vaccine
c.
Subunit vaccine
d.
DNA vaccine
e.
Biolistic vaccine
22.
Which of the following cytokines is a common therapeutic target for treating autoimmune diseases?
a.
Tumor necrosis factor-α (TNF-α)
b.
Concanavalin A (ConA)
c.
Lipopolysaccharide (LPS)
